FDA Approves Breakthrough Pancreatic Cancer Pill That Nearly Doubles Survival Time In Studies
Mind Body Green | 27.08.2026 17:45
The U.S. Food and Drug Administration has approved daraxonrasib1, sold under name Rasonque, the first targeted therapy of its kind for metastatic pancreatic cancer. This approval comes months ahead of schedule, following a 500-person clinical trial where the once-daily pill nearly doubled median survival compared to standard chemotherapy. Pancreatic cancer has long been considered one of the hardest forms of the disease to treat, making these results even more noteworthy.
